FLEURY S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.41 BRL | +2.86% |
|
+1.91% | -20.12% |
| May. 10 | Fleury Seeks Acquisitions | CI |
| May. 10 | Transcript : Fleury S.A., Q1 2024 Earnings Call, May 10, 2024 |
| Sales 2024 * | 7.8B 1.47B | Sales 2025 * | 8.35B 1.58B | Capitalization | 7.86B 1.48B |
|---|---|---|---|---|---|
| Net income 2024 * | 627M 118M | Net income 2025 * | 774M 146M | EV / Sales 2024 * | 1.48 x |
| Net Debt 2024 * | 3.7B 698M | Net Debt 2025 * | 3.22B 608M | EV / Sales 2025 * | 1.33 x |
| P/E ratio 2024 * |
12.7
x | P/E ratio 2025 * |
10.3
x | Employees | 27,300 |
| Yield 2024 * |
5.11% | Yield 2025 * |
5.89% | Free-Float | 43.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fleury S.A.
More press releases
| 1 day | +2.86% | ||
| 1 week | +1.91% | ||
| Current month | +2.56% | ||
| 1 month | -2.83% | ||
| 3 months | -7.92% | ||
| 6 months | -18.22% | ||
| Current year | -20.12% |
1 week
13.86
14.75
1 month
13.8615.07
Current year
13.6918.08
1 year
13.6918.96
3 years
12.8926.55
5 years
12.8932.47
10 years
6.1032.47
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 00-12-31 | |
| Director of Finance/CFO | 63 | 21-07-22 | |
| Chief Tech/Sci/R&D Officer | 48 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | - | |
| Director/Board Member | 78 | 13-04-08 | |
João Teixeira
BRD | Director/Board Member | 58 | 21-04-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.43% | 2 M€ | -14.14% | ||
| 0.24% | 14 M€ | -4.02% | ||
| 0.02% | 4 M€ | -4.41% | - | |
| 0.01% | 112 M€ | +5.18% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 14.41 | -0.62% | 3,797,100 |
| 24-06-04 | 14.5 | -0.28% | 2,951,700 |
| 24-06-03 | 14.54 | +3.49% | 3,925,200 |
| 24-05-31 | 14.05 | -0.64% | 2,592,800 |
| 24-05-29 | 14.14 | -2.48% | 2,414,500 |
Delayed Quote Sao Paulo, June 05, 2024 at 04:07 pm EDT
More quotes
Fleury S.A. specializes in clinical diagnosis, treatment and analysis services.
At the end of 2018, the group operated a network of 187 patient care centers and 23 hospital centers under Fleury, Weinmann, Clínica Felipe Mattoso, a +, Labs a + and Diagnoson a + brands.
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
14.41
BRL
Average target price
19.33
BRL
Spread / Average Target
+34.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.12% | 1.49B | |
| -22.91% | 7.77B | |
| +75.58% | 4.51B | |
| -2.10% | 2.67B | |
| +5.60% | 2.76B | |
| -47.96% | 2.09B | |
| -16.87% | 1.72B | |
| +18.29% | 1.22B | |
| -44.77% | 1.12B | |
| -6.62% | 983M |
- Stock Market
- Equities
- FLRY3 Stock
